Adagio raised $750M+ for an antibody against future variants. It failed against Omicron
Since the pandemic began in the spring of 2020, Tillman Gerngross has raised more than half a billion dollars for his startup Adagio and their promise to develop a so-called broadly neutralizing coronavirus antibody that could snare any variant.
When Omicron broke out over Thanksgiving, bringing a strain that threatened to evade widely-used antibody treatments from Eli Lilly and Regeneron, Adagio’s $ADGI soared 34% as Gerngross’ predictions appeared to come true. Early computational analyses suggested Adagio’s antibody, ADG20, currently in pivotal trials, should retain full efficacy against the variant.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 142,800+ biopharma pros reading Endpoints daily — and it's free.